A randomized phase 2 study of combination cediranib and olaparib versus olaparib alone as recurrence therapy in platinum-sensitive ovarian cancer

BACKGROUND: Olaparib is an oral poly(ADP-ribose) polymerase inhibitor and cediranib is an oral anti-angiogenic with activity against VEGFR-1, 2, and 3. Both agents have antitumor activity in women with recurrent ovarian cancer, and the combination of these agents was active and had manageable toxici...

詳細記述

保存先:
書誌詳細
出版年:Lancet Oncol
主要な著者: Liu, Joyce F., Barry, William T., Birrer, Michael, Lee, Jung-Min, Buckanovich, Ronald J., Fleming, Gini F., Rimel, BJ, Buss, Mary K., Nattam, Sreenivasa, Hurteau, Jean, Luo, Weixiu, Quy, Philippa, Whalen, Christin, Obermayer, Lisa, Lee, Hang, Winer, Eric P., Kohn, Elise C., Ivy, S. Percy, Matulonis, Ursula A.
フォーマット: Artigo
言語:Inglês
出版事項: 2014
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4294183/
https://ncbi.nlm.nih.gov/pubmed/25218906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(14)70391-2
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料